Patient informed consent was obtained during outpatient consultation. In all patients, the aim was BAVM occlusion, starting by EE and completion by SRS or surgery if necessary.
T he results of ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations) and SIVMS (Scottish Intracranial Vascular Malformation Study) associate interventional treatment of unruptured brain arteriovenous malformations (uBAVMs) with higher rates of stroke or death than medical management alone. 1, 2 In light of this new evidence, neurovascular specialists had to reconsider deliberate treatment of uBAVM. 3 At our institution, there is multidisciplinary agreement on starting treatment of BAVMs with endovascular embolization (EE) whenever reasonable, followed by stereotactic radiosurgery (SRS) or microsurgical extirpation if necessary to attain cure.
The issue of this retrospective study is to determine the outcome of ARUBA-eligible patients undergoing primary EE in a pre-ARUBA era.
Materials and Methods
The conduct of this study was approved by the Medical Ethics Committee of Ghent University. Data, analytic methods, and study materials will be made available to any researcher for purposes of reproducing the results or replicating the procedure. Requests to receive these materials should be sent to the corresponding author, who will maintain their availability.
Participants
We included all patients with an ARUBA trial profile who underwent EE as primary interventional therapy for a uBAVM between February 2001 and October 2014 ( Figure I in the online-only Data Supplement). 1 The inception point for follow-up was the date of BAVM diagnosis.
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SRS was performed with a Linac-based radiosurgery technique on a dedicated linear accelerator (Novalis TX; Varian Medical Systems, CA). Radiation consisted in delivering a single 15 to 20 Gy dose to the 80% isodose line encompassing the uBAVM.
Outcomes
The modified Rankin Scale (mRS) was assessed by the first author, who was not involved in the clinical care. 3 Final mRS scores were obtained from data in the hospital medical record, or in case patients were not seen in the past 3 years, by a face-to-face interview. The last follow-up mRS score is the primary end point of this study. 3 Any event of symptomatic stroke or BAVM-related death is a secondary end point. Events within 30 days after treatment, or at any time after SRS, were considered treatment complications. 5 The annual hemorrhage rate was calculated by dividing the number of hemorrhages by the total follow-up years from diagnosis until stroke or last observation. Occlusion of the BAVM was documented by catheter angiography and was a secondary end point. 6 IBM SPSS statistics 23 was used for statistical analyses. Ninetyfive percent confidence intervals (95% CIs) are reported. P values reported are 2-sided.
Results
Sixty-one patients were eligible for analysis. The Table provides a summary of demographic and clinical characteristics of these patients and a comparison with patients from ARUBA. 1 Twenty-five patients (41%) underwent EE as the only treatment modality. Thirty-five patients (57%) received combined therapy of EE followed by SRS. A microsurgical resection was performed on one of these patients after SRS. One patient (2%) underwent EE followed by a microsurgical resection.
Follow-up continued for a median of 60 months (interquartile range, 29-91 months). At last follow-up, 4 patients (7%, 4/61) had ongoing treatment plans.
Forty-seven patients (77.0%; 95% confidence interval [CI], 66.5%-87.6%) had no clinical impairment (mRS score of ≤1) at last follow-up (Figure 1 ). Five patients (8.2%) died: 2 because of BAVM-related intracranial hemorrhage within 30 days of EE, 2 others because of hemorrhagic stroke >30 days after SRS, and 1 because of a BAVM-unrelated acute myocardial infarction (last live mRS score of 1).
Twelve patients (19.7%; 95% CI, 9.7%-29.6%) reached the outcome of symptomatic stroke or death because of BAVM or intervention (Table I in the online-only Data Supplement). The annual bleeding rate was 2.67% (total follow-up was 338 person-years). In fatal postoperative bleedings, angiography showed occlusion in 1 case immediately after treatment. In the other 3, occlusion was not yet expected.
Forty-four patients (77.2%; 95% CI, 66.3%-88.1%; 44/57) obtained angiographic cure (Table II in 
Discussion
In this series of 61 consecutive ARUBA-eligible patients treated by EE as primary intervention, 19.7% suffered a stroke or died. Compared with the as-treated ARUBA analysis, we registered less strokes or fatal outcomes than in the intervention group (19.7% versus 35.7%; odds ratio, 2.27; 95% CI, 1.067-4.824), but still 3× more than in the medical group (19.7% versus 6.4%; odds ratio, 0.28; 95% CI, 0.11-0.73).
1
The Kaplan-Meier curve, estimating the event probability in the presented series, remained stable under 0.2 for 105 months ( Figure 2 ). This steady state would offer the curve of ARUBA medical group time and opportunity to cross above it. However, by a late event at 106 months, the event probability in the present series raised to 27% (Table I in the online-only Data Supplement, patient 9). ARUBA long-term results are awaited to see whether the slope of the conservatively managed patients will continue its upward trend. We achieved a standard occlusion rate of 29.8% with EE alone and a high overall occlusion rate of 73.7% in combination with SRS. 2, 5, 7 Unfortunately, 8 patients chose to discontinue treatment before occlusion was attained. Most of these patients had an uncomplicated treatment course. When treating in fragments, motivation of patients is crucial in achieving cure. Periprocedural mortality was low (3%) and in accordance with other articles. 4, 8 Nevertheless, in uBAVM, mortality remains a fateful aspect of embolization. Mortality was associated with postoperative hemorrhage, which seems to occur more frequently in embolization of uBAVM. 8 Hemorrhage is attributed to thrombotic occlusion of the draining vein or failure to regulate arterial pressure in perinidal arterioles. 9 Until other evidence is provided, we refrained from postoperative heparinization.
Late mortality too was associated with hemorrhage in 2 cases. 10 Both patients underwent SRS, which alters the flow dynamics in the residual nidus. 10 The annual rupture rate in the present series (2.67%) was not higher than the natural rupture risk, even with the inclusion of treatment-induced bleedings.
11
Considered together, the results of our study bring into question the generalizability of the conclusions of ARUBA to uBAVM patients treated by EE as primary treatment modality. However, differences in patient baseline characteristics (Table) may have also contributed to the disparity in outcomes between both studies.
A major limitation of our study is its retrospective design. Selection bias toward good candidates for embolization is real. Only a fraction of BAVM patients did not undergo embolization in that period, but the number was unfortunately not documented prospectively ( Figure I in the onlineonly Data Supplement). Retrospective mRS evaluation could have also biased inclusion according to ARUBA criteria. When possible, post-treatment mRS was obtained by a faceto-face interview to increase reliability. Despite the variability in follow-up (mean, 71.5 months; interquartile range, 29-91), the observation time allowed detection of handicaps sustaining for at least 2 years. 
Conclusions
In uBAVM, Onyx embolization alone or combined with SRS achieves a high occlusion rate. Morbidity remains a challenge, even if it seems lower than in the ARUBA trial.
Disclosures
None. 
